Moderna's bird flu vaccine performs well in first human trial
Cambridge-based Moderna Therapeutics on Thursday unveiled early data from its first human trial, saying that its bird flu vaccine had easily outperformed a placebo.
Moderna is focused exclusively on an approach known as messenger RNA, which recruits the body's own cells to create proteins to fight disease. The privately-held company employs 460 people and has attracted more than $1 billion in investments and partnership deals, but has revealed few details abo ut its pipeline in recent years.
The…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Max Stendahl Source Type: news
More News: Bird Flu | Bird Flu (H5N1 Avian Influenza) Vaccine | Health Management | Partnerships | Pharmaceuticals | Vaccines